The role of nuclear medicine in the diagnosis of cancer of unknown origin.
Cancer of unknown origin (CUO) is defined by the absence of any primary tumour in biopsy-proved metastatic cancer. CUO accounts for a 5-10% of all malignancies. These tumors have a specific biology with clinical characteristics of rapid progression and atypical metastases. Diagnostic evaluation is directed at the identification of treatable subset. Accurate diagnostic workup is crucial because both prognosis and survival rates depend mainly on detection of the primary tumor site. Although these patients undergo extensive imaging procedures, nuclear medicine techniques are under-utilized despite their ability of providing molecular information. Positron emission tomography has an emerging role in this clinical challenge along with other nuclear medicine methods including, bone scan, thyroid scintigraphy.
Demir
H
H
Department of Nuclear Medicine, Kocaeli University School of Medicine, Kocaeli, Turkey.
Berk
F
F
Raderer
M
M
Plowman
P N
PN
Lassen
U
U
Daugaard
G
G
Clausen
M
M
Bohuslavizki
K H
KH
Peters
M
M
Harmer
C
C
Malamitsi
J
J
Aktolun
C
C
D014408:Biomarkers, Tumor / Q000097:blood; D001859:Bone Neoplasms / Q000000981:diagnostic imaging / Q000556:secondary; D001842:Bone and Bones / Q000000981:diagnostic imaging; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008207:Lymphatic Metastasis / Q000000981:diagnostic imaging; D009382:Neoplasms, Unknown Primary / Q000175:diagnosis / Q000000981:diagnostic imaging*; D011379:Prognosis; D019275:Radiopharmaceuticals; D014055:Tomography, Emission-Computed; D015899:Tomography, Emission-Computed, Single-Photon
D014408:Biomarkers, Tumor; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18